Indications
Dashboard
CKD Associated With T2D
HF LVEF ≥40%

FINEARTS-HF*: the only MRA trial leading to FDA approval for adult patients with HF LVEF ≥40%1,10

FINEARTS-HF was a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial with a median follow-up period of 2.7 years.1

Criteria & baseline characteristics

*In the FINEARTS-HF trial, HF LVEF ≥40% was defined as HFmrEF or HFpEF.21

CV=cardiovascular; HF=heart failure; HF LVEF=heart failure with left ventricular ejection fraction; HFmrEF=heart failure with mildly reduced ejection fraction; HFpEF=heart failure with preserved ejection fraction; MRA=mineralocorticoid antagonist.

Trial Design Efficacy Safety

Key criteria and baseline characteristics​

FINEARTS-HF (N=6001)1

Select inclusion criteria22

  • Adults aged ≥40 years
  • Diagnosis of HF (NYHA Class II-IV), ambulatory or hospitalized
    primarily for HF
  • LVEF ≥40% documented ≤12 months ago
  • On diuretic treatment at least 30 days prior to randomization
  • Elevated levels of natriuretic peptides*
  • Evidence of structural heart disease

Select exclusion criteria22

  • MI or any event that could have reduced the EF within 90 days prior
    to randomization
  • eGFR <25 mL/min/1.73 m2 at screening or randomization
  • Serum potassium >5.0 mEq/L at screening or randomization

Select baseline
patient characteristics1,10

  • Mean age: 72 years
  • Mean LVEF: 53%
  • LVEF ≥50%: 64%
  • NYHA Class II: 69%
  • NYHA Class III: 30%
  • Median NT-proBNP: 1041 pg/mL
  • Mean eGFR: 62 mL/min/1.73 m2
  • eGFR <60 mL/min/1.73 m2: 48%
  • Randomized ≤7 days from HF event: 20%
  • Type 2 diabetes mellitus: 41%
  • Loop diuretics: 87%
  • ACEi or ARB: 79%
  • ARNi: 9%
  • SGLT2i: 14%
  • GLP-1 RA: 2.8%
  • Beta-blocker: 85%

*Elevated natriuretic peptide levels were defined as NT-proBNP ≥300 pg/mL (or BNP ≥100 pg/mL) in patients with sinus rhythm and no ongoing diagnosis of paroxysmal atrial fibrillation, or NT-proBNP ≥900 pg/mL (or BNP ≥300 pg/mL) in patients with atrial fibrillation.10,22

ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; ARNi=angiotensin receptor-neprilysin inhibitor; BNP=B-type natriuretic peptide; EF=ejection fraction; eGFR=estimated glomerular filtration rate; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HF=heart failure;
LVEF=left ventricular ejection fraction; MI=myocardial infarction; NT-proBNP=N-terminal pro-B-type natriuretic peptide; NYHA=New York Heart Association; SGLT2i=sodium-glucose cotransporter 2 inhibitor.